Judith Anderton

729 total citations
6 papers, 188 citations indexed

About

Judith Anderton is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Judith Anderton has authored 6 papers receiving a total of 188 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 1 paper in Pharmacology. Recurrent topics in Judith Anderton's work include HER2/EGFR in Cancer Research (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Judith Anderton is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Judith Anderton collaborates with scholars based in United Kingdom, France and Singapore. Judith Anderton's co-authors include D. Mark Hickinson, Robert W. Wilkinson, Gayle Marshall, Georgina Speake, Bernard Barlaam, Donald Ogilvie, John P. Vincent, Teresa Klinowska, Cath Trigwell and Konstantina Grosios and has published in prestigious journals such as Clinical Cancer Research, Anti-Cancer Drugs and ACS Medicinal Chemistry Letters.

In The Last Decade

Judith Anderton

5 papers receiving 180 citations

Peers

Countries citing papers authored by Judith Anderton

Since Specialization

Citations

This map shows the geographic impact of Judith Anderton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith Anderton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith Anderton more than expected).

Fields of papers citing papers by Judith Anderton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith Anderton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith Anderton. The network helps show where Judith Anderton may publish in the future.

Co-authorship network of co-authors of Judith Anderton

This figure shows the co-authorship network connecting the top 25 collaborators of Judith Anderton. A scholar is included among the top collaborators of Judith Anderton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith Anderton. Judith Anderton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

#	Work	Indexed citations
1	A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression 2023 ·Clinical Cancer Research ·Sarah B. Gitto, (unknown), Gareth Davies, Sushil Kumar, Krista Kinneer, Haineng Xu, Arthur Lewis, Srinivas Mamidi, (unknown), Hyoung Kim, Judith Anderton, (unknown), (unknown), Steven Coats, Robert W. Wilkinson, Eric J. Brown, Daniel J. Powell, Fiona Simpkins	16
2	Detecting bliss synergy in in vivo combination studies with a tumor kinetic model 2019 ·Pharmaceutical Statistics ·(unknown), Paolo Vicini, Steven Novick, Judith Anderton, Gareth M. Davies, Gina D’Angelo, (unknown), Binbing Yu, Jay Harper, Rajesh Narwal, Lorin Roskos, Harry Yang	1
3	Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors 2013 ·ACS Medicinal Chemistry Letters ·Bernard Barlaam, Judith Anderton, Peter Ballard, Robert H. Bradbury, Laurent Hennequin, D. Mark Hickinson, Jason G. Kettle, (unknown), Teresa Klinowska, Christine Lambert‐van der Brempt, Cath Trigwell, John P. Vincent, Donald Ogilvie	31
4	AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer 2010 ·Clinical Cancer Research ·D. Mark Hickinson, Teresa Klinowska, Georgina Speake, John P. Vincent, Cath Trigwell, Judith Anderton, Sarah Beck, Gayle Marshall, Sara Davenport, Rowena Callis, Elizabeth Mills, Konstantina Grosios, Paul D. Smith, Bernard Barlaam, Robert W. Wilkinson, Donald Ogilvie	95
5	Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? 2009 ·Anti-Cancer Drugs ·Yuri Rukazenkov, Georgina Speake, Gayle Marshall, Judith Anderton, Barry R. Davies, Robert W. Wilkinson, D. Mark Hickinson, Alan Swaisland	43
6	A pharmacological comparison of gefitinib (IRESSA) and erlotinib 2006 ·Georgina Speake, Gayle Marshall, Judith Anderton, (unknown), Armelle Logié, (unknown), R. McCormack, P H Smith, B. R. Holloway, Barry R. Davies, D. Mark Hickinson	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact